enVVeno Medical Corp
NVNONasdaq
$10.80
↑ +5.2%Jul 17 close · end-of-day
Price
1Y↓ -92.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.1M
Enterprise Value
-$17.9M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$18.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-79.2%
ROIC
—
Debt / Equity
—
Net Cash
$24.9M
Return 1Y
-94.1%
Company profile
enVVeno Medical Corporation focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the. treatment of severe deep venous chronic venous insufficiency.
- CEO
- Robert A. Berman
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 30
- Headquarters
- California
- Website
- envveno.com
Earnings
NVNO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$5.89↓ -24.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.1M | -$16.9M | -$24.9M | -$25.2M | -$23.8M | -$20.9M |
| Net income | -$9.1M | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
| Diluted EPS | — | — | -$2.20 | -$1.91 | -$44.53 | -$33.06 |
| Operating cash flow | -$7.7M | -$11.8M | -$15.6M | -$18.9M | -$16.8M | -$15.6M |
| Free cash flow | -$7.9M | -$12.2M | -$15.7M | -$18.9M | -$16.9M | -$15.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.5M | -$6.2M | -$6.7M | -$5.0M | -$7.0M | -$4.9M | -$4.0M | -$4.1M |
| Net income | -$5.0M | -$5.6M | -$6.2M | -$4.5M | -$6.7M | -$4.5M | -$3.7M | -$3.8M |
| Diluted EPS | -$0.31 | -$0.35 | -$43.56 | -$7.75 | -$0.33 | -$0.23 | -$24.75 | -$5.89 |
| Operating cash flow | -$3.9M | -$4.3M | -$5.1M | -$4.0M | -$3.7M | -$4.4M | -$3.4M | -$3.2M |
| Free cash flow | -$3.9M | -$4.3M | -$5.1M | — | — | -$4.4M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 22, 2026
Jun 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Duhay Francis | Sale | 140 | $10.31 | $1,442.70 | filing |
| 2026-03-12 | Duhay Francis | Sale | 140 | $11.52 | $1,613.14 | filing |
| 2025-12-11 | Duhay Francis | Sale | 4,900 | $0.36 | $1,742.44 | filing |
| 2025-09-15 | Duhay Francis | Sale | 4,900 | $0.83 | $4,067.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.